Skip to content
EVENT / TOPICHistorical

Moderna Cancer Vaccine Trial Success Sends Stock Down 25%

1 reports1 sources10/23/2026 updated

Current overview (not historical)

AI overview

Moderna's personalized cancer vaccine mRNA-4157 demonstrated a 42% reduction in melanoma recurrence or death risk and an 82% two-year recurrence-free survival rate in a phase 2 trial. Despite the positive data, the stock fell over 25% as the trial focused solely on melanoma and personalized vaccine production requires a six-week manufacturing timeline, raising investor concerns about broader commercial viability.

Written with AI from the reporting · updated 10/23/2026

Latest developmentOct 23, 12:51
Moderna shares drop up to 25% despite positive melanoma cancer vaccine data
Explore the timeline, relations and evidence
Expand the detailed fact route and sources

Story route

A station-by-station route from the first public evidence onward; every station carries its own evidence and uncertainty.

  1. 1Unclassified fact stationOct 23, 00:00recorded Oct 23, 13:16single source

    Moderna股价因癌症疫苗数据虽好但未达预期而下跌25%

    Read original source ↗ BeInCryptoReplay this moment in the explorer
    Evidence & revisions · 1 source records
    Subject：
    moderna
    Action：
    股价下跌
    Object：
    股票
    Occurred (fact side)：
    Oct 23, 00:00
    BeInCrypto ↗Report pageOriginal / first version
    Published (valid side)：
    Oct 23, 12:51
    First seen (known side)：
    Oct 23, 13:16
    Fact stationSingle source · one-sided claim

    Copy may have been revised later; time replay is bounded. Layer labels group reading only, not causation between layers.

Uncertainty marks flag where to check the sources; they are not proven causation.

Report timeline

Explore every side through dated source reports.

Oct 23
  1. BeInCryptoRelated fact: single source
    Moderna shares drop up to 25% despite positive melanoma cancer vaccine data

    Report first recorded Oct 23, 13:16

    Moderna (MRNA) shares fell as much as 25% on Thursday, even though its personalized cancer vaccine, Intismeran autogene paired with Merck’s Keytruda, cut melanoma recurrence or death risk by 42% in certain patients. The combination showed an 82% two-year recurrence-free survival rate versus 70% on Keytruda alone, and cut the risk of distant spread or death by 38%. However, the trial covered only one tumor type, and the personalized vaccine production takes six weeks, posing a manufacturing challenge. Full phase 3 results are expected at the ESMO conference this weekend.

    Read original source ↗

Event discussion

Reader opinions are hosted on GitHub Discussions; posting requires a GitHub account. Comments are not verified facts.

Open GitHub Discussions